#NewAseBioMember | “Being part of AseBio means joining a dynamic community committed to advancing biotechnology in Spain and beyond”
Meet our new member Schrödinger. We sponke with María José Aliaga, Associate Account Manager.
AseBio. What does your company's work bring to the table and what is its strength?
María José Aliaga. Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com , follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
AseBio. What is AseBio for you?
María José Aliaga. For us, AseBio represents a platform to connect, collaborate, and advocate for innovation within the life sciences. Being part of AseBio means joining a dynamic community committed to advancing biotechnology in Spain and beyond.
AseBio. When did you first hear about AseBio?
María José Aliaga. We first became aware of AseBio through our collaborations and interactions with Spanish biotech companies and research institutions over the past few years. Its growing influence and reputation in the European biotech landscape caught our attention.
AseBio. What do you expect from being part of an association like AseBio?
María José Aliaga. We hope to foster meaningful partnerships, stay informed about regional trends, and contribute to shaping biotech policies and initiatives. We also look forward to engaging with innovators and thought leaders to collectively drive scientific and technological progress.
AseBio. What is the biggest challenge facing the biotech sector or your company?
María José Aliaga. One of the biggest challenges in the biotech sector is bridging the gap between early-stage discoveries and clinical or commercial success. For Schrödinger, a key challenge is ensuring that advanced computational tools are widely adopted and understood, to unlock their full potential in transforming R&D productivity.